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Abstract 
Background: To determine and compare the 
serum hepcidin levels and conventional markers of 
iron status in patients of β- thalassaemia major with 
controls. 
Methods: Forty patients of β- thalassaemia major 
who were not on iron chelation therapy and 40 
normal controls were included in this study. 
Hemoglobin level, red blood cell count and 
hematocrit of the study group were determined. 
Hepcidin levels along with serum iron, serum 
ferritin and total iron binding capacity were 
determined . 
Results:Serum hepcidin level was found to be 
reduced in patients (426.21 pg/ml) as compared to 
controls (757.45 pg/ ml). 
Conclusion: Determination of hepcidin 
concentration is a useful indicator for high risk of 
iron toxicity in patients of beta thalassaemia with 
multiple transfusions 
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Introduction 
Thalassaemias are hereditary anemias resulting from 
defects in the production of haemoglobin. The World 
Health Organization (WHO) recognizes thalassaemia 
as the world’s most prevalent genetic disorder. The 
estimated live births who suffer from β-thalassaemia 
in Pakistan are five to nine thousand per year with a 
carrier state of 9.8 million.1Iron overload is the main 
cause of mortality and morbidity in patients with β 
thalassaemia major.2 Though frequent red cells 
transfusion has been identified as the leading cause of 
iron overload yet it is also established that non-
transfusion dependent patients also develop iron 
overload.3  This harmful iron over load results in many 
complications like growth retardation, delayed sexual 
maturation and later on involvement of liver, heart 
and endocrine glands.4 Excess cellular iron is 
extremely harmful to cells by facilitating the 
production of reactive oxygen species which damage 
cellular proteins, lipids, and DNA.5  
Hepcidin plays a vital role in iron homeostasis in 
humans, regulating iron absorption from the intestine 
and its recycling by macrophages.6There are three 
forms of hepcidin: 25aa (human), 22aa and 20aa 
peptide. Human hepcidin gene (HAMP) is located on 
chromosome 19q13.1 and is mainly expressed in the 
liver. 7,8  Hepcidin controls the dietary iron absorption 
and release of iron from macrophages.9 
Several physiologic and pathologic processes regulate 
the production of hepcidin.10 In iron-loading anaemias 
like thalassaemia, hepcidin synthesis is regulated by 
Growth Differentiation Factor 15 (GDF 15) which is 
secreted by marrow erythroblasts resulting in low 
Hepcidin expression and increased intestinal iron 
absorption. In patients of β-thalassaemia major with 
iron overload, serum hepcidin levels are lower than 
would be expected because of the increased but 
ineffective erythropoiesis. The reduction of 
erythropoietic activity by transfusions, partially relieve 
the suppression of hepcidin.11Although  any hepcidin 
agonist is not yet available, but it can be valuable in 
prevention of iron overload in non- transfused β- 
thalassemia patients. Hepcidin therapy may also help 
in the intervals of transfusion when hepcidin falls and 
GI iron absorption increases.12  
 
Patients and Methods 
This case control study was conducted in the 
department of Haematology, University of Health 
Sciences Lahore in collaboration with Sundas 
Foundation Lahore and Capital Hospital Islamabad. 
Forty diagnosed patients of β-thalassemia major, who 
had received at least five transfusions and were not on 
iron chelation therapy (Group A) along with 40 
healthy age and sex matched controls (Group B), were 
included. Three mL was delivered into the gel 
vacutainer for the estimation of serum iron, TIBC, 
ferritin and hepcidin and two ml into the EDTA 
vacutainer for the estimation of hemoglobin levels. 
Hemoglobin levels were measured by Sysmex Xi 1800 
automated Hematology analyzer. Serum iron and 
TIBC were determined spectrophotometrically using 
Fer-Color kit from Wiener Lab Argentina and Serum 
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ferritin was determined by using human ferritin 
enzyme immunoassay test kit (Gen-Way Bio tech Inc. 
USA).Hepcidin levels were determined by using 
human hepcidin ELISA kit(Elabsciences, China).The 
methodology of given ELISA kit was based on 
Sandwich-ELISA.The micro ELISA plate provided in 
the kit was pre-coated with an antibody specific to 
hepcidin. Samples were added to the micro ELISA 
plate wells and bound by the specific antibody. Then a 
biotinylated detection antibody specific for hepcidin 
and Avidin-Horseradish Peroxidase (HRP) conjugate 
was added to each micro plate well successively and 
incubated. Free components were washed away. The 
substrate solution was added to each well. Blue color 
was observed. The enzyme-substrate reaction was 
terminated by the addition of a sulphuric acid solution 
and the color turned yellow. The optical density (OD) 
was measured spectrophotometrically at a wavelength 
of 450 nm ± 2 nm. The value of OD was proportional 
to the concentration of hepcidin.The comparisons of 
various variables for association or significance were 
done by using Independent student t -Test while 
correlation between different variables was established 
by using Pearson correlation test. Probability level less 
than or equal to 0.05 was considered as statistically 
significant. 
Results 
Forty transfusion dependent β-thalassemia major 
patients and 40 age and sex matched healthy controls 
were included in the study. Both groups comprised of 
20 males and 20 females patients. The median age of 
patients was 36 (24- 42) months. Similarly in controls it 
was also 36 (33- 40) months. 
Table 1-Haemoglobin, Serum Iron, TIBC, 
Ferritin and Hepcidin levels  
Parameters Patients  
(n=40) 
Controls 
 (n=40) 
P-value 
Hemoglobin 
g/dl 
 6.46± 1.63  12.92±0.69  ------- 
Iron (µg/dl) 1002.5  
(622.5-2099.0) 
296.5 
(252.5-410.0) 
0.001 
TIBC (µg/dl) 197.5 
(161.5-209.7) 
276.00 
(259.2-301.5) 
0.001 
Ferritin 
(ng/ml) 
6    603.0 
    (317.7-897.7) 
33.43(24.1-
43.1) 
0.001 
Hepcidin 
(pg/ml) 
426.2 
(278.8-951.1) 
757.4(424.4-
1074.4) 
0.001 
 
 Haemoglobin concentration was lower (6.46± 1.63 
g/dL) in patients as compared to controls (12.92 ± 0.69 
g/dL). In both groups serum iron profile was 
determined which comprised of serum iron, TIBC and 
ferritin. Serum iron level was found to be higher in 
patients (1002.50 µg/dl)as compared to controls i.e. 
(296.50 µg/dl), while serum TIBC was 197.50 and 
276.0 µg/dl in patients and controls respectively.  
Student t-test was applied on the given data of 
patients and controls. Serum ferritin levels were also 
higher in patients (603.03 ng/ml) as compared to 
controls (33.43 ng/ml). Serum hepcidin was reduced 
in patients 426.21 pg/ml as compared to controls i.e., 
757.45 pg/ml(Table 1).Significant differences between 
two groups were observed (p-value <0.001) (Table 1). 
 
 
 
 
 
 
 
Discussion 
Iron overload in thalassaemia patients is fatal and a 
major cause of morbidity and mortality. Extraordinary 
iron deposition leads to marked cellular damage and 
organ dysfunction. 13,14 . It affects multiple organs and 
excessive iron accumulation results in progressive 
dysfunction of heart, endocrine glands, and liver. 
Extensive iron deposits are associated with cardiac 
hypertrophy and dilatation and rarely fibrosis. Iron 
induced hepatic fibrosis and cirrhosis can be seen in 
many patients. Iron toxicity in anterior pituitary gland 
results in disturbed sexual maturation and secondary 
amenorrhea. Diabetes mellitus is seen in 5% of adults. 
Long term iron deposition also damages thyroid, 
parathyroid, and adrenal glands. Iron overload is 
attributed mainly to blood transfusions, but it is also 
caused by increased iron absorption.4 
There are different methods for detection of iron status 
in overload conditions. The liver is the main site of 
iron overload and liver iron correlates closely with 
total body iron. Estimation of liver iron concentration 
is the most precise method of estimation of body iron.  
But this facility is currently not common in Pakistan.  
Non-availability of MR T2 makes the assessment of 
cardiac iron virtually impossible. Serum ferritin 
Fig-1:Scatter plot shows a 
negative correlation between 
serum hepcidin and TIBC 
Fig-2: Scatter plot shows 
a positive correlation 
between serum 
hepcidin and ferritin. 
Journal of Rawalpindi Medical College (JRMC); 2016;20(3):206-208 
 208 
measured at regular intervals (at least 3 months) has 
some therapeutic and prognostic use. In this study we 
analyzed and compared serum hepcidin level and 
conventional markers of iron status in β Thalassemia 
major patients and controls.Hepcidin is a key regulator 
of iron homeostasis and a mediator of anemia of 
inflammation. It is a 25aa peptide, a regulatory protein 
produced by the hepatocytes, regulating intestinal iron 
absorption and its distribution throughout the body.15 
It is, therefore, emerging as an important diagnostic 
marker. 
In the present study we found that serum hepcidin 
levels were lower in patients when compared to 
controls. A significant difference between two groups 
was observed (p-value 0.001).Similar observations 
have been made in another study, where serum 
hepcidin levels were low in thalassaemia major 
patients.16 In another study the serum hepcidin levels 
were similar in both, patients and controls, because 
these patients were on chelation therapy.17  
In this study we used Pearson correlation to find 
correlation of serum hepcidin with serum ferritin, 
TIBC and Hb. We did not find a significant correlation 
of hepcidin with serum ferritin, TIBC and Hb in 
patients (r= 0.224, p-value= 0.164), (r = -0.63, p-
value=0.697) and (r= -0.224, p-value= 0.164) 
respectively. These results were in accordance with the 
previous report that showed no significant correlation 
between serum hepcidin and ferritin levels as a marker 
of iron overload in thalassaemia major patients.18 
Hepcidin is found to have low positive correlation 
with ferritin and negative correlation with Hb and 
TIBC. Similar result has been reported in another 
study where serum hepcidin had positive correlation 
with serum ferritin.17 
 
Conclusion 
1.Hepcidin concentration in patients with iron-loading 
anaemias is decreased and consequently leads to 
increased iron absorption.  
2.Determination of hepcidin concentration is useful to 
identify the patients at higher risk of iron toxicity. 3. 
Developing hepcidin agonists will be useful in 
transfused thalassaemia patients 
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